References
- 1. As toul P. Pleurodesis for recurrent malignant pleural effusions: the quest for the Holy Grail. [Editorial]. Eur J Cardiothorac Surg 2011; 40: 277-9.
- 2. Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg 2006; 29: 829-38.
- 3. Debeljak A, Kecelj P, Triller N, Letonja S, Kern I, Debevec L, et al. Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions. J BUON 2006; 11: 463-7.
- 4. Crnjac A, Sok M, Kamenik M. Impact of pleural effusion pH on the efficacy of thoracoscopic machanical pleurodesis in patients with brest carcinoma. Eur J Cardiothorac Surg 2004; 26: 432-6.
- 5. Mitchell RN, Cotran RS. Tissue repair: cell regeneration and fibrosis. In: Kumar V, Cotran RS, Robbins SL, editors. Robins Basic Pathology. 7th edition. Philadelphia: Saunders; 2003. p. 61-78.
- 6. Lorenz PH, Longaker MT. Wounds: biology, pathology, and management. In: Norton JA, Barie PS, Bollinger RR, Chang AE, Lowry SF, Mulvihill SJ, et al, editors. Surgery: basic science and clinical evidence. 2nd edition. New York: Springer; 2008. p. 191-208.
- 7. Schultz GS, Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen 2009; 17: 153-62.
- 8. Midwood KS, Valenick Williams L, Schwarzbauer JE. Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol 2004; 36: 1031-37.
- 9. Noncollagen components of the extracellular matrix. In: Lodish H, Berk A, editors. Molecular cell biology. 4th edition. New York: W. H. Freeman; 2000. p. 985-93.
- 10. Antony VB, Nasreen N, Mohammed KA, Sriram PS, Frank W, Schoenfeld N, et al. Talc pleurodesis: basic fibroblast growth factor mediates pleural fibrosis. Chest 2004; 126: 1522-8.
- 11. Teixeira LR, Vargas FS, Acencio MMP, Sabrina C. Ribeiro SC, Sales RKB, et al. Blockage of vascular endothelial growth factor (VEGF) reduces experimental Pleurodesis. Lung Cancer 2011; 74: 392-5.
- 12. Gary Lee YC, Teixeira LR, Devin CJ, Vaz MAC, Vargas FS, Thompson PJ, et al. Transforming growth factor-β2 induces pleurodesis significantly faster than talc. Am J Respir Crit Care Med 2001; 163: 640-4.
- 13. Duysinx BC, Corhay JL, Hubin L, Nguyen D, Henket M, Louis R. Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions. Respir Med 2008; 102: 1708-14.
- 14. Genofre EH, Vargas FS, Acencio MMP, Antonangelo L, Teixeira LR, Marchi E. Talc pleurodesis: evidence of systemic inflammatory response to small size talc particles. Respir Med 2009; 103: 91-7.
- 15. Thickett DR, Armstrong L, Christie SJ, Millar AB. Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 164: 1601-5.
- 16. Koenigsberg R, Maierhofer J, Steininger Tanja, Kienzer, G, Dittrich C. Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab. Radiol Oncol 2014; 48: 184-8.
- 17. Hooper CE, Elversb KT, Welshc GI, Millard AB, Maskell NA. VEGF and sVEGFR-1 in malignant pleural effusions: Association with survival and pleurodesis outcomes. Lung Cancer 2012; 77: 443-9.
- 18. Ishii H, Yazawab T, Satob H, Suzukib T, Ikedab M, Hayashia Y, et al. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer 2004; 45: 325-37.
- 19. Mercurio AM, Lipscomb EA, Bachelder RE. Non-angiogenic functions of VEGF in breast cancer. J Mammary Gland Biol Neoplasia 2005; 10: 283-90.
- 20. Auer J, Keller U, Schmidt M, Ott O, Fietkau R, Distel LV. Individual radiosensitivity in a breast cancer collective is changed with the patients’ age. Radiol Oncol 2014; 48: 80-6.
- 21. Kovač V, Smrdel U. Meta-analyses of clinical trials in patients with non-small cell lung cancer. Neoplasma 2004; 51: 334-40.
- 22. Tuzi A, Lombardi D, Crivellari D, Militello L, Perin T, La Grassa M. Epirubicin and docetaxel as neoadjuvant treatment of hormone receptor positive, HER-2 negative breast cancer: findings from two successive phase II studies. Radiol Oncol 2013; 47: 57-62.
- 23. Debevec L, Erzen J, Debeljak A, Crnjac A, Kovac V. Exploratory thoracotomy and its influence on the survival of patients with lung cancer. Wien Klin Wochenschr 2006; 118: 479-84.
- 24. Kovac V, Zwitter M, Rajer M, Marin A, Debeljak A, Smrdel U, Vrankar M. A phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for malignant pleural mesothelioma. Anticancer Drugs 2012; 23: 2308-8.
- 25. Klecka ME, Maldonado F. Symptom relief after large-volume thoracentesis in the absence of lung perfusion. Chest 2014; 145: 1141-3.
- 26. Crnjac A. The significance of thoracoscopic mechanical pleurodesis for the treatment of malignant pleural effusions. Wien Klin Wochenschr 2004; 116(Suppl 2): 28-32.
- 27. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
- 28. Light RW. What I have learned in the past 40 Years. Clin Chest Med 2013; 34: xi.
- 29. Zebrowski BK, Yano S, Liu W, Shaheen RM, Hicklin DJ, Putnam JB, et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res 1999; 5: 3364-8.
- 30. Teixeira LR, Vargas FS, Acencio MMP, Antonangelo L, Novaes NP, Costa JD, et al. Influence of parecoxib (cox-2 inhibitor) in experimental pleurodesis. Respir Med 2009; 103: 595-600.
- 31. Zahid I, Routledge T, Bille A, Scarci M. What is the best treatment for malignant pleural effusions? Interact CardioVasc Thorac Surg 2011; 12: 818-23.
- 32. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-β – an excellent servant but a bad master. J Transl Med 2012; 10: 18 3.